Search | Clinical Trials Finder

Conditions: Osteopenia, Osteoporosis
Interventions: risedronate, alendronate; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 2
States / cities: Gainesville, Florida • New Orleans, Louisiana

Conditions: Diabetic Foot Ulcer
Interventions: doxycycline, placebo gel; Drug
Lead sponsor: NanoSHIFT LLC; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Coronary Heart Disease
Interventions: montelukast, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Tourette Syndrome
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 44
States / cities: Sun City, Arizona • Springdale, Arkansas • Long Beach, California + 41 more

Conditions: Leukemia
Interventions: theophylline; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 68
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 51 more

Conditions: Graft vs Host Disease, Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation
Interventions: Questionnaires, Blood Sample, Stool Sample, Clinical data; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Umbilical Hernia, Obesity
Interventions: TAPB Group, RSB Group, conversion to general anesthesia; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Parkinson's Disease, Multiple Sclerosis
Interventions: EMST, Sham; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 35 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cerebrotendinous Xanthomatosis (CTX)
Interventions: Not listed
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 44
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 38 more

Conditions: Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
Interventions: Risperidone, Other atypical antipsychotic drugs; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 8 Years to 16 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 13
States / cities: San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 10 more

Conditions: Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
Interventions: The Angel® Catheter; Device
Lead sponsor: BiO2 Medical; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 21
States / cities: Los Angeles, California • San Diego, California • Loveland, Colorado + 18 more

Conditions: Coronary Artery Bypass
Interventions: Prasugrel, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 4
States / cities: San Francisco, California • Gainesville, Florida • Chicago, Illinois + 1 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 50
States / cities: Huntsville, Alabama • Montgomery, Alabama • Gilbert, Arizona + 47 more

Conditions: Seizures
Interventions: Carbamazepine, Gabapentin, Lamotrigine; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 60 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more

Conditions: Attention Deficit Hyperactivity Disorder, Comorbid Social Anxiety Disorder
Interventions: Atomoxetine hydrochloride, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Wildomar, California • Bradenton, Florida • Gainesville, Florida + 17 more

Conditions: Type I Diabetes
Interventions: NNC0361-0041, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 16
States / cities: Orange, California • San Francisco, California • Stanford, California + 13 more

Conditions: Bipolar Disorder
Interventions: lamictal; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 46
States / cities: Dothan, Alabama • Scottsdale, Arizona • San Diego, California + 39 more

Conditions: Orthodontic Tooth Movement
Interventions: Invisalign 7-day wear protocol, Invisalign 3-day wear protocol; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 30 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Lung Diseases, Interstitial
Interventions: BI 1015550, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 59
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more

Conditions: Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
Interventions: Tipifarnib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 171
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more

Conditions: Small Cell Lung Cancer
Interventions: ABBV-706, Atezolizumab, Etoposide, Carboplatin, Lurbinectedin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 12
States / cities: New Haven, Connecticut • Gainesville, Florida • Ocala, Florida + 9 more

Conditions: End Stage Renal Disease, Renal Failure
Interventions: PAL-40 Active, PAL-40 Placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 21 Years and older
Enrollment: 2,003 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 36
States / cities: Birmingham, Alabama • Menlo Park, California • Palo Alto, California + 33 more

Conditions: Myalgia, Hypercholesterolemia, Hyperlipidemia
Interventions: PPD10558, Atorvastatin, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 67
States / cities: Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more

Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm
Interventions: Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 108
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 84 more

Search by objective public record fields.

Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose

Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers

Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease

Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia

Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT

Abdominal Wall Block Study

Expiratory Muscle Training for Persons With Neurodegenerative Disease

Cerebrotendinous Xanthomatosis (CTX) Prevalence Study

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

The Angel® Catheter Pivotal Clinical Trial

Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis

Dosing Flexibility Study in Patients With Rheumatoid Arthritis

Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.

Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder

A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients

Clinical Trial to Assess the Efficacy of Reducing the Aligners' Wear Protocol

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Homocysteine Study (HOST)

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)